These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20361006)

  • 21. Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Expert Rev Endocrinol Metab; 2008 Nov; 3(6):671-690. PubMed ID: 30764058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.
    Tilinca MC; Tiuca RA; Burlacu A; Varga A
    Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34209532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide Use in the Management of Type 2 Diabetes Mellitus.
    Kyriacou A; Ahmed AB
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2554-2567. PubMed ID: 27713366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
    Blonde L; Anderson JE; Chava P; Dendy JA
    Curr Med Res Opin; 2019 May; 35(5):793-804. PubMed ID: 30370783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin degludec + liraglutide: a complementary combination.
    Stinkens K; Peene B; Mathieu C
    Expert Opin Biol Ther; 2016 Sep; 16(9):1171-7. PubMed ID: 27484310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Liraglutide].
    Takahashi T; Odawara M
    Nihon Rinsho; 2011 May; 69(5):883-9. PubMed ID: 21595276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
    Wismann P; Pedersen SL; Hansen G; Mannerstedt K; Pedersen PJ; Jeppesen PB; Vrang N; Fosgerau K; Jelsing J
    Physiol Behav; 2018 Aug; 192():72-81. PubMed ID: 29540315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
    Jacobsen LV; Flint A; Olsen AK; Ingwersen SH
    Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.
    Valentine V; Goldman J; Shubrook JH
    Diabetes Ther; 2017 Aug; 8(4):739-752. PubMed ID: 28721686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.
    Yabe D; Seino Y
    Clin Med Insights Endocrinol Diabetes; 2011; 4():47-62. PubMed ID: 22879794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
    Oda H; Mori A; Lee P; Saeki K; Ishioka K; Arai T; Sako T
    Res Vet Sci; 2013 Oct; 95(2):381-8. PubMed ID: 23632200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Krishnan G; Jothydev S
    Int J Gen Med; 2012; 5():317-22. PubMed ID: 22536087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
    Kaneko S; Ueda Y; Tahara Y
    Eur Surg Res; 2018; 59(5-6):349-360. PubMed ID: 30537714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.